Literature DB >> 18083276

No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease.

Rochelle E Tractenberg1, Paul S Aisen, Gregory R Hancock, G William Rebeck.   

Abstract

This study sought to determine if there are detectible influences on the symptoms of Alzheimer's disease (AD) from the genetic risk factor for AD, the epsilon4 allele of apolipoprotein-E (APOE). Using data from two cohorts of AD patients, a cross-sectional latent variable model of AD was tested with three symptom factors explaining variability in the observed variables after taking a general neurological factor into account. No significant influence of epsilon4 was detected. APOE's effect in AD may occur prior to clinical symptoms, or may simply be more subtle than these instruments can detect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18083276      PMCID: PMC2740902          DOI: 10.1016/j.neurobiolaging.2007.11.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  3 in total

1.  A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

Authors:  P S Aisen; K L Davis; J D Berg; K Schafer; K Campbell; R G Thomas; M F Weiner; M R Farlow; M Sano; M Grundman; L J Thal
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

2.  Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach.

Authors:  Rochelle E Tractenberg; Paul S Aisen; Myron F Weiner; Jeffrey L Cummings; Gregory R Hancock
Journal:  Alzheimers Dement       Date:  2006-10       Impact factor: 21.566

3.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Authors:  Paul S Aisen; Kimberly A Schafer; Michael Grundman; Eric Pfeiffer; Mary Sano; Kenneth L Davis; Martin R Farlow; Shelia Jin; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2003-06-04       Impact factor: 56.272

  3 in total
  1 in total

1.  Analytic methods for factors, dimensions and endpoints in clinical trials for Alzheimer's disease.

Authors:  R E Tractenberg
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.